Myostine 5mg/tab 30 Tablets by Vital Research

Usage

1. Establish your research objective — selectivity comparison studies benefit from a fixed single daily dose; begin at 5 mg to document baseline androgenic and anabolic response.
2. Administer the tablet orally with a small meal; YK-11's steroidal structure confers reasonable oral bioavailability, though consistent fed-state timing reduces inter-day variability.
3. Record dose timing precisely — the estimated half-life of YK-11 is approximately 6–10 hours, suggesting twice-daily splitting (e.g. 5 mg AM / 5 mg PM) may sustain more consistent plasma levels at 10 mg/day protocols.
4. Draw baseline bloods before Week 1: include total testosterone, LH, FSH, ALT, AST, and haematocrit — these establish the pre-research reference points against which SARM-related changes are measured.
5. Re-test at Week 4 (mid-protocol): HPG suppression markers and liver enzymes are the critical selectivity-vs.-steroid comparison data points — document deviations from baseline.
6. Upon protocol completion, initiate PCT within 24–48 hours of the final tablet; the steroidal SARM classification of YK-11 warrants a structured post-cycle approach rather than the watchful waiting sometimes applied to non-steroidal SARMs.

Warnings

Frequently asked questions

What does 'tissue selectivity' actually mean when comparing YK-11 to anabolic steroids?

Tissue selectivity means YK-11 preferentially activates androgen receptors in muscle and bone by recruiting specific co-activator proteins, rather than triggering uniform receptor saturation across all androgen-sensitive tissues as classical AAS do. In practice, this reduces androgenic signalling in the prostate and scalp relative to an equivalent anabolic dose of testosterone — though selectivity is partial, not absolute.

Are SARMs like Myostine genuinely safer than traditional steroids in terms of side effects?

SARMs carry a narrower documented side-effect profile in certain tissues — reduced aromatization risk and lower androgenic signal in non-target organs — but 'safer' is dose- and context-dependent. YK-11 still suppresses the hypothalamic–pituitary–gonadal axis and shows hepatocyte stress in vitro, meaning liver monitoring and post-cycle support remain necessary, just as with conventional androgens.

Where does the tissue selectivity of YK-11 break down compared to other SARMs?

YK-11's steroidal backbone makes its selectivity profile less clean than non-steroidal SARMs such as Ostarine. Preclinical data indicate stronger AR binding affinity but also a higher likelihood of HPG-axis suppression and potential hepatotoxic liability — areas where classical selectivity advantages erode. Researchers should treat YK-11 as occupying the high-potency, moderate-selectivity segment of the SARM spectrum.

Why is 5mg per tablet significant for dosing precision with Myostine?

At 5 mg/tablet, Vital Research Myostine is the highest per-tablet concentration in the series, allowing researchers to achieve a 5, 10, or 15 mg daily dose using whole tablets — no splitting required. This preserves content uniformity validated by HPLC testing and eliminates dose inconsistency introduced by manual tablet division.

How does the blister format of Myostine 30 tablets support accurate research protocols?

Each 30-tablet blister carries a unique lot code linked to a compound-specific certificate of analysis documenting HPLC-verified YK-11 potency and LAL endotoxin results. Individual blister sealing under GMP-aligned conditions protects tablet integrity from moisture and oxidation, ensuring dose consistency from tablet one through tablet thirty across the full research cycle. (2) angle_used

Manufacturer

Vital Research's distribution and logistics model is organized around compound-specific blister units shipped with their individual quality documentation — each 30-tablet Myostine blister leaves the facility paired with a lot-specific certificate of analysis rather than a generic facility-wide quality statement. Order fulfillment is structured to maintain cold-chain compatibility where required, and discrete, tamper-evident outer packaging protects product integrity during transit. Traceability is embedded at the logistics layer: the unique lot code printed on each blister links directly to HPLC potency data and LAL endotoxin results for that specific YK-11 batch, allowing end recipients to cross-reference quality documentation against the physical unit received. GMP-aligned handling procedures govern the warehouse-to-dispatch workflow, ensuring that the analytical standards applied during production are not undermined by inadequate storage or fulfillment conditions.